
Clinical Trials - February 28, 2017
Data from ALK results in significant change to the GINA asthma management strategy
ALK has announced that for the first time, allergy immunotherapy is now recommended as a treatment option in the Global Initiative for Asthma (GINA) report: Global Strategy for Asthma Management and Prevention. This global strategy is a practical resource developed to guide healthcare professionals and policy makers, and represents the latest clinical evidence and medical practice […]

Clinical Trials - June 8, 2015
ALK Partner Testing Allergy Drug
ALK’s partner MSD has produced encouraging results from a North American Phase III clinical trial of ALK’s investigational sublingual allergy immunotherapy tablet for the treatment of house dust mite allergic rhinitis. The trial demonstrated a statistically significant improvement in the primary endpoint in favor of HDM SLIT-tablet compared with placebo, according to BioSpace.com. The primary endpoint […]